ROCKWELL MEDICAL INC
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
RMTI$7.31-2.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 2023 and 2022
(In thousands, except share and par value amounts)
| December 31,2023 | December 31,2022 | |
|---|---|---|
| ASSETS | ||
| Cash and Cash Equivalents | $8,983 | $10,102 |
| Investments Available-for-Sale | 1,952 | 11,390 |
| Accounts Receivable, net of a reserve of $81 for 2023 and $33 for 2022 | 10,901 | 6,259 |
| Inventory, net | 5,871 | 5,814 |
| Prepaid and Other Current Assets | 1,063 | 1,745 |
| Total Current Assets | 28,770 | 35,310 |
| Property and Equipment, net | 6,402 | 2,194 |
| Inventory, Non-Current | 178 | 1,276 |
| Right of Use Assets - Operating, net | 2,713 | 3,943 |
| Right of Use Assets - Financing, net | 1,903 | 2,468 |
| Intangible Assets, net | 10,759 | — |
| Goodwill | 921 | 921 |
| Other Non-Current Assets | 527 | 523 |
| Total Assets | $52,173 | $46,635 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Insurance Financing Note Payable | $244 | $503 |
| Accounts Payable | 4,516 | 4,053 |
| Accrued Liabilities | 7,149 | 7,702 |
| Deferred Consideration, Current | 2,500 | — |
| Lease Liabilities - Operating, Current | 1,381 | 1,483 |
| Lease Liabilities - Financing, Current | 558 | 522 |
| Deferred License Revenue, Current | 46 | 1,731 |
| Term Loan, Current - Net of Issuance Costs and Premium Accretion | — | 1,631 |
| Customer Deposits | 243 | 66 |
| Total Current Liabilities | 16,637 | 17,691 |
| Lease Liabilities - Operating - Long-Term | 1,433 | 2,581 |
| Lease Liabilities - Financing - Long-Term | 1,530 | 2,088 |
| Term Loan - Long-Term, Net of Issuance Costs and Premium Accretion | 8,293 | 7,555 |
| Deferred License Revenue - Long-Term | 475 | 2,600 |
| Deferred Consideration - Long-Term | 2,500 | — |
| Long Term Liability - Other | 14 | 14 |
| Total Liabilities | 30,882 | 32,529 |
| Commitments and Contingencies (See Note 15) | ||
| Stockholders’ Equity: | ||
| Preferred Stock, $0.0001 par value, 2,000,000 shares authorized, 15,000 shares issued and outstanding at December 31, 2023 and 2022 | — | — |
| Common Stock, $0.0001 par value, 170,000,000 shares authorized, 29,130,607 and 12,163,673 shares issued and outstanding at December 31, 2023 and 2022 | 3 | 1 |
| Additional Paid-in Capital | 418,487 | 402,701 |
| Accumulated Deficit | (397,198) | (388,759) |
| Accumulated Other Comprehensive (Loss) Income | (1) | 163 |
| Total Stockholders’ Equity | 21,291 | 14,106 |
|---|---|---|
| Total Liabilities and Stockholders’ Equity | $52,173 | $46,635 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.